Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


Bristol-Myers Squibb Withdraws Lipostat From NZ

Bristol-Myers Squibb Withdraws Lipostat From New Zealand

Bristol-Myers Squibb is withdrawing its cholesterol-lowering therapy LIPOSTAT® (pravastatin) from New Zealand, Managing Director, Australia/New Zealand, Mr John Kilborn, announced today.

Mr Kilborn said that the Company would work with the medical profession to minimise the effect on patients of the withdrawal.

He stressed that the decision was not related to the safety or efficacy of Lipostat, which had been proven in extensive clinical trials in New Zealand and other countries to be a safe and effective therapy.

“This has been an extremely difficult business decision forced upon the Company by pricing issues. Unfortunately we have reached a point where Lipostat is no longer commercially viable in New Zealand,” he said.

Mr Kilborn said that the policies of the New Zealand pharmaceutical pricing authority, PHARMAC, had precipitated the withdrawal.

“Having funded the LIPID study in New Zealand at a cost of many millions of dollars, it is extremely disappointing that BMS has been unable to achieve any commercial return on this research,” he said.

“It is also ironic that regulatory authorities around the world have acknowledged the unique data in support of pravastatin. As recently as last month, the Australian reimbursement authority confirmed that there are clear differences between statins.

“The argument of ‘class effect’ to justify New Zealand-style reference pricing has been seriously called into question by the recently global withdrawal of cerivastatin. This is just another example that evidence-based outcomes for one agent cannot be assumed for another.”

Mr Kilborn said that the end result of PHARMAC’s policies was a reduction in the number of proven therapeutic agents available to doctors. In the case of Lipostat, doctors will no longer have the option of prescribing the world’s most well-researched statin therapy.

Bristol-Myers Squibb has expressed its concerns in the past about the effects of PHARMAC policies on health outcomes, as well as their role in the diminution of medical research and industry activity in New Zealand. These policies led to the Company’s current policy of not conducting clinical research in New Zealand.

“As an organisation committed to extending and enhancing life, Bristol-Myers Squibb is disappointed that it has to withdraw from New Zelaland a therapy that is one of the most well-researched medicines available,” Mr Kilborn said.


© Scoop Media

Business Headlines | Sci-Tech Headlines


I Sing The Highway Electric: Charge Net NZ To Connect New Zealand

BMW is turning Middle Earth electric after today announcing a substantial contribution to the charging network Charge Net NZ. This landmark partnership will enable Kiwis to drive their electric vehicles (EVs) right across New Zealand through the installation of a fast charging highway stretching from Kaitaia to Invercargill. More>>


Watch This Space: Mahia Rocket Lab Launch Site Officially Opened

Economic Development Minster Steven Joyce today opened New Zealand’s first orbital launch site, Rocket Lab Launch Complex 1, on the Mahia Peninsula on the North Island’s east coast. More>>


Marketing Rocks!
Ig Nobel Award Winners Assess The Personality Of Rocks

A Massey University marketing lecturer has received the 2016 Ig Nobel Prize for economics for a research project that asked university students to describe the “brand personalities” of three rocks. More>>


Nurofen Promotion: Reckitt Benckiser To Plead Guilty To Misleading Ads

Reckitt Benckiser (New Zealand) intends to plead guilty to charges of misleading consumers over the way it promoted a range of Nurofen products, the Commerce Commission says. More>>


Half A Billion Accounts, Including Xtra: Yahoo Confirms Huge Data Breach

The account information may have included names, email addresses, telephone numbers, dates of birth, hashed passwords (the vast majority with bcrypt) and, in some cases, encrypted or unencrypted security questions and answers. More>>


Rural Branches: Westpac To Close 19 Branches, ANZ Looks At 7

Westpac confirms it will close nineteen branches across the country; ANZ closes its Ngaruawahia branch and is consulting on plans to close six more branches; The bank workers union says many of its members are nervous about their futures and asking ... More>>

Interest Rates: RBNZ's Wheeler Keeps OCR At 2%

Reserve Bank governor Graeme Wheeler kept the official cash rate at 2 percent and said more easing will be needed to get inflation back within the target band. More>>


Get More From Scoop

Search Scoop  
Powered by Vodafone
NZ independent news